BR112013031019A2 - teste diagnóstico molecular para câncer - Google Patents

teste diagnóstico molecular para câncer

Info

Publication number
BR112013031019A2
BR112013031019A2 BR112013031019A BR112013031019A BR112013031019A2 BR 112013031019 A2 BR112013031019 A2 BR 112013031019A2 BR 112013031019 A BR112013031019 A BR 112013031019A BR 112013031019 A BR112013031019 A BR 112013031019A BR 112013031019 A2 BR112013031019 A2 BR 112013031019A2
Authority
BR
Brazil
Prior art keywords
cancer
diagnostic test
molecular diagnostic
molecular
test
Prior art date
Application number
BR112013031019A
Other languages
English (en)
Portuguese (pt)
Inventor
Max Bylesjo
Timothy Davison
Steve Deharo
Charlie Gourley
Dennis Paul Harkin
Laura A Hill
Katherine E Keating
Richard Kennedy
Andrena Mccavigan
Fionnuala Mcdyer
Caroline Michie
Eamonn J O'brien
Jude O'donnell
Vitali Proutski
Claire Trinder
Andreas Winter
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of BR112013031019A2 publication Critical patent/BR112013031019A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112013031019A 2011-06-02 2012-06-04 teste diagnóstico molecular para câncer BR112013031019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492488P 2011-06-02 2011-06-02
PCT/US2012/040805 WO2012167278A1 (en) 2011-06-02 2012-06-04 Molecular diagnostic test for cancer

Publications (1)

Publication Number Publication Date
BR112013031019A2 true BR112013031019A2 (pt) 2017-03-21

Family

ID=47259970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031019A BR112013031019A2 (pt) 2011-06-02 2012-06-04 teste diagnóstico molecular para câncer

Country Status (13)

Country Link
US (1) US10260097B2 (https=)
EP (1) EP2715348B1 (https=)
JP (2) JP6067686B2 (https=)
KR (1) KR20140044341A (https=)
CN (1) CN103733065B (https=)
AU (1) AU2012261820B2 (https=)
BR (1) BR112013031019A2 (https=)
CA (1) CA2838086A1 (https=)
EA (2) EA025926B1 (https=)
IL (1) IL229681A0 (https=)
MX (1) MX2013014065A (https=)
SG (2) SG195208A1 (https=)
WO (1) WO2012167278A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
EP2667193A1 (en) * 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
WO2014055398A1 (en) * 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
MX2015006955A (es) * 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
GB201313342D0 (en) * 2013-07-26 2013-09-11 Cancer Rec Tech Ltd Biomarkers
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
GB201409478D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Pro-angiogenic signature
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016028638A1 (en) * 2014-08-18 2016-02-25 Drexel University Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment
WO2016133374A1 (ko) * 2015-02-17 2016-08-25 싸이퍼롬, 인코퍼레이티드 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법
CN105160208A (zh) * 2015-05-29 2015-12-16 杭州奥视图像技术有限公司 用于疾病亚型问题的基于网络的聚类方法
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US10650325B2 (en) * 2015-07-31 2020-05-12 Microsoft Technology Licensing, Llc Deterministic message distribution
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
JP6942135B2 (ja) * 2016-01-25 2021-09-29 サノフイＳａｎｏｆｉ 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法
US20190127805A1 (en) * 2016-03-15 2019-05-02 Almac Diagnostics Limited Gene signatures for cancer detection and treatment
JP6899848B2 (ja) 2016-12-28 2021-07-07 公益財団法人がん研究会 抗ｖｅｇｆｒ−２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット
CN107037210A (zh) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用
US20200200760A1 (en) * 2017-05-16 2020-06-25 Lankenau Institute Of Medical Research Compositions comprising ligands to rhob protein and the uses thereof
EP3879535B1 (en) * 2017-06-13 2024-12-11 BostonGene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
JP7316270B2 (ja) * 2017-06-19 2023-07-27 インビタエ コーポレイション 統合算出および実験的深層変異学習フレームワークを介した遺伝子およびゲノム変異体の解釈
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
JP7455757B2 (ja) * 2018-04-13 2024-03-26 フリーノーム・ホールディングス・インコーポレイテッド 生体試料の多検体アッセイのための機械学習実装
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN112955260A (zh) * 2018-06-27 2021-06-11 定量癌症诊断有限责任公司 生物样品保持器和处理器
CN109585011A (zh) * 2018-10-26 2019-04-05 朱海燕 胸痛患者的病症诊断方法及机器可读存储介质
MX2021005646A (es) * 2018-11-14 2021-08-11 Beyondspring Pharmaceuticals Inc Métodos de tratamiento de cáncer con agentes de unión a tubulina.
WO2021016402A1 (en) * 2019-07-22 2021-01-28 Mission Bio, Inc. Using machine learning to optimize assays for single cell targeted dna sequencing
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
US11049590B1 (en) 2020-02-12 2021-06-29 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
PE20230609A1 (es) * 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
CN112489800B (zh) * 2020-12-03 2024-05-28 安徽医科大学第一附属医院 一种前列腺癌患者的预后评估系统及其应用
CN116312814B (zh) * 2021-12-02 2024-09-27 复旦大学 一种肺腺癌分子分型模型的构建方法、设备、装置以及试剂盒
CN114624441B (zh) * 2022-03-04 2025-07-18 中国人民解放军空军军医大学 跨膜蛋白43作为胰腺癌肿瘤诊断标志物的应用
CN115902223B (zh) * 2022-11-15 2025-08-26 中国人民解放军空军军医大学 蛋白生物标志物在胃癌诊断中的应用
CN116863995B (zh) * 2023-08-29 2024-05-14 北京大学第一医院 Alpk2，itga11，esyt1，cdh17在预测药物出血中的应用
CN118393140B (zh) * 2024-04-24 2025-04-11 英科众康(厦门)科技有限公司 基于适配体/抗体新型夹心式介导的检测技术在泛癌标志物c1qc诊断中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US6946442B2 (en) 1994-11-30 2005-09-20 Asif Syed Ahmed Method of hastening cervical ripening
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6998234B2 (en) * 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
AU2003281325A1 (en) * 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CN102321584B (zh) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1756306A2 (en) * 2004-05-14 2007-02-28 Ludwig Institute For Cancer Research Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
AU2005263972A1 (en) * 2004-07-23 2006-01-26 Astrazeneca Ab Method of predicting the responsiveness of a tumor to erbB receptor drugs
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
CA2601157A1 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
AU2006292278B2 (en) * 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7919261B2 (en) * 2005-12-05 2011-04-05 Merck Sharp & Dohme Corp. Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP2363711A1 (en) * 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US20090275633A1 (en) * 2006-04-13 2009-11-05 Oncomethylome Sciences Sa Novel Tumour Suppressor
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR20090071603A (ko) 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
US20090082218A1 (en) 2007-08-13 2009-03-26 Paul Harkin 3'-Based sequencing approach for microarray manufacture
WO2009042814A1 (en) * 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Early diagnosis and treatment of drug resistance in muc1-positive cancer
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
CN101910416A (zh) * 2007-11-09 2010-12-08 健泰科生物技术公司 在癌症患者中诊断性使用的方法和组合物
CA2707900A1 (en) * 2007-12-07 2009-06-18 Oregon Health & Science University Methods to determine if a subject will respond to a bcr-abl inhibitor
US8114593B2 (en) * 2008-03-12 2012-02-14 University Of Medicine And Dentistry Of New Jersey Cancer biomarker genes and gene products and methods for using the same
WO2009149297A1 (en) * 2008-06-04 2009-12-10 The Arizona Board Regents, On Behalf Of The University Of Arizona Diffuse large b-cell lymphoma markers and uses therefor
US20110195064A1 (en) * 2008-06-06 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Survival predictor for diffuse large b cell lymphoma
AU2009270851A1 (en) * 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
JP5606438B2 (ja) * 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
WO2010088688A2 (en) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
AU2010297344A1 (en) * 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
CA2811015A1 (en) 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
AU2011352167A1 (en) 2010-12-28 2013-07-11 Caris Mpi, Inc. Molecular profiling for cancer
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
EP2667193A1 (en) 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.

Also Published As

Publication number Publication date
CN103733065B (zh) 2017-12-15
JP6067686B2 (ja) 2017-01-25
EP2715348B1 (en) 2019-04-10
JP2014516552A (ja) 2014-07-17
EA201391805A1 (ru) 2014-03-31
NZ618191A (en) 2015-04-24
KR20140044341A (ko) 2014-04-14
EP2715348A1 (en) 2014-04-09
US20140342924A1 (en) 2014-11-20
US10260097B2 (en) 2019-04-16
IL229681A0 (en) 2014-01-30
EA025926B1 (ru) 2017-02-28
WO2012167278A1 (en) 2012-12-06
CA2838086A1 (en) 2012-12-06
SG195208A1 (en) 2013-12-30
AU2012261820B2 (en) 2017-01-19
JP2017079772A (ja) 2017-05-18
EA201691257A1 (ru) 2017-02-28
MX2013014065A (es) 2014-06-23
EP2715348A4 (en) 2015-10-07
SG10201604497UA (en) 2016-07-28
CN103733065A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
BR112013031019A2 (pt) teste diagnóstico molecular para câncer
IL239196A0 (en) Molecular diagnosis of cancer
ZA201508689B (en) Molecular diagnostic test for cancer
HUE036509T2 (hu) Kazetta sterilitási vizsgálathoz
IL244472A0 (en) Molecular diagnostic test for lung cancer
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
EP2681855A4 (en) RADIO TEST
BR112014013745A2 (pt) teste de imunosseleção de multiplex
BR112015003931A2 (pt) composição de teste para detecção de cãncer
BR112013020540A2 (pt) métodos para preparação de conjugados
EP2730040A4 (en) RADIO TRANSMISSION TEST
EP2748608A4 (en) LUNG CANCER TESTS
EP2627333A4 (en) Combination treatment of cancer
PT2876447T (pt) Método para deteção de cancro
SG11201601721UA (en) Molecular diagnostic test for oesophageal cancer
BR112013012063A2 (pt) teste não destrutivo para compósitos flexíveis
EP3936851C0 (en) SYSTEM FOR INTRODUCING FLOW INTO A SAMPLE PROBE
EP2742358A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
IL227295A0 (en) Diagnostic method
BR112013012241A2 (pt) método diagnóstico de teste de pneu
BRPI1008243A2 (pt) teste para detecção de tumor adrenal
BR112013011545A2 (pt) método para medir posição de componente
DE112012003417A5 (de) Strommessgerät
EP2812694A4 (en) TESTS AND METHOD FOR DIAGNOSIS OF EGG CANCER
EP2732287A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.